OncoGenex Pharmaceuticals Inc. (OGXI) and Teva Pharmaceutical (TEVA) announced Monday morning that the Phase III SYNERGY trial comparing the combination of custirsen and standard first-line docetaxel/prednisone therapy to docetaxel/prednisone alone in men with metastatic castrate-resistant prostate cancer did not meet the primary endpoint.
OncoGenex Pharmaceuticals gapped open dramatically lower Monday and is now down 5.20 at $4.50 on strong volume. The stock has plummeted to a new low for the year.
For comments and feedback contact: editorial@rttnews.com
Business News